AstraZeneca bets on gene editing for broad range of new drugs

January 29, 2015 7:14 AM

4 0

AstraZeneca bets on gene editing for broad range of new drugs

LONDON (Reuters) - AstraZeneca said on Thursday it had struck four research collaborations in the hot area of genome editing as it bets on a new technology to deliver better and more precise drugs for a range of diseases.

The academic and commercial tie-ups will allow British-based AstraZeneca to use so-called CRISPR technology across its entire drug discovery platform in areas such as oncology, cardiovascular, respiratory and immune system medicine.

Read more

To category page

Loading...